July 22, 2025
1 min watch
On this video unique, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, famous the continuing efforts to outline lengthy COVID and up to date information suggesting physicians aren’t treating lupus nephritis “arduous sufficient.”
“[Healio Rheumatology’s July cover story] actually speaks for itself, as a result of it addresses the strengths and weak point and points which can be essential to rheumatologists surrounding the Nationwide Academies of Sciences, Engineering and Medication’s definition of lengthy COVID, and the way it will have an effect on us and our sufferers,” he mentioned. “Dr. Harvey V. Fineberg participated — we’re very grateful — it’s a wonderful learn, and I’ve an editorial on it that I feel you’ll be concerned with.”
Calabrese moreover mentioned the latest proliferation of knowledge and updates relating to lupus, together with a latest examine suggesting that 3 years of remission from lupus nephritis seems to be the minimal time interval that protects towards impaired kidney operate and the accrual of organ harm.
Healio Rheumatology’s protection of the info additionally options views from Michelle Petri, MD, MPH, director of the Hopkins Lupus Heart, and David A. McLain, MD, MACR, FACP, FRCP, govt director of the Alabama Society for the Rheumatic Illnesses.
“Lupus is in all places proper now,” Calabrese mentioned. “And up to date information recommend that we aren’t treating it arduous sufficient. Extended remedy, even in remission, could also be wanted for renal survival.
“Test it out — Dr. McLain provides a extremely good commentary with some examples from his personal apply,” he added.
Lastly, Calabrese highlighted the most recent efforts to make disease-altering therapies in osteoarthritis a actuality.
“[Osteoarthritis] is an orphan illness in rheumatology in some ways, though it’s ubiquitous in our inhabitants,” he mentioned. “And at last, there seems to be some fascinating targets on the way in which.”
For extra data:
Leonard H. Calabrese, DO, might be reached at calabrl@ccf.org or at rheumatology@healio.com.
Sources/Disclosures
Collapse
Disclosures:
Calabrese stories being a medical advisor for OpenEvidence, in addition to skilled relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.
